Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Spero Therapeutics, Inc. (SPRO) had Return on Equity of -21.61% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-9.55M |
|
-- |
|
-- |
|
$9.93M |
|
$-9.93M |
|
$0.37M |
|
$-9.55M |
|
$-9.55M |
|
$-9.55M |
|
$-9.55M |
|
$-9.55M |
|
$-9.55M |
|
$-9.93M |
|
$-9.93M |
|
57.97M |
|
57.97M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$51.58M |
|
-- |
|
$1.18M |
|
$52.77M |
|
$8.43M |
|
-- |
|
$0.13M |
|
$8.56M |
|
$44.20M |
|
$44.20M |
|
$44.20M |
|
58.15M |
|
| Cash Flow Statement Financials | |
$10.51M |
|
-- |
|
-- |
|
$40.27M |
|
$50.77M |
|
$10.51M |
|
$1.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$10.51M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-21.61% |
-21.61% |
|
-18.10% |
|
-21.61% |
|
$0.76 |
|
$0.18 |
|
$0.18 |
|